Mesa Laboratories/$MLAB
1D1W1MYTD1Y5YMAX
Capital at risk
About Mesa Laboratories
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
- Ticker
- $MLAB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 717
- Headquarters
- Lakewood, United States
- Website
- www.mesalabs.com
MLAB Metrics
BasicAdvanced
$680M
141.12
$0.86
0.93
$0.48
0.53%
Price and volume
Market cap
$680M
Beta
0.93
52-week high
$132.70
52-week low
$61.42
Average daily volume
156K
Dividend rate
$0.48
Financial strength
Current ratio
1.794
Quick ratio
1.163
Long term debt to equity
0.811
Total debt to equity
0.855
Dividend payout ratio (TTM)
73.63%
Interest coverage (TTM)
1.72%
Profitability
EBITDA (TTM)
45.437
Gross margin (TTM)
64.21%
Net profit margin (TTM)
1.92%
Operating margin (TTM)
9.00%
Effective tax rate (TTM)
48.69%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
3.29%
Return on equity (TTM)
2.66%
Valuation
Price to earnings (TTM)
141.117
Price to revenue (TTM)
2.706
Price to book
3.6
Price to tangible book (TTM)
-8.98
Price to free cash flow (TTM)
12.779
Free cash flow yield (TTM)
7.83%
Free cash flow per share (TTM)
9.506
Dividend yield (TTM)
0.40%
Forward dividend yield
0.53%
Growth
Revenue change (TTM)
3.04%
Earnings per share change (TTM)
-855.05%
3-year revenue growth (CAGR)
4.43%
10-year revenue growth (CAGR)
11.04%
3-year earnings per share growth (CAGR)
37.13%
10-year earnings per share growth (CAGR)
-10.93%
What the Analysts think about MLAB
Analyst ratings (Buy, Hold, Sell) for Mesa Laboratories stock.
Analyst projections of the future price of Mesa Laboratories stock.
Bulls say / Bears say
Operating income more than doubled to $7.03 million in 1Q27, driven by lower third-party labor and consultant spend, supply-chain efficiencies, and a favorable product mix. (Reuters)
Revenues increased 1.0% to $60.14 million in 1Q27, demonstrating resilience amid a challenging macroeconomic environment. (Reuters)
Operating cash flow rose to $14.74 million in 1Q27, enabling an $8.7 million debt reduction and ending the quarter with $30.7 million in cash, bolstering financial flexibility. (Reuters)
Net income plunged 40.3% to $2.83 million in 1Q27 due to a swing to non-operating expenses from prior-year currency gains, highlighting volatility in earnings. (Reuters)
Top-line growth was a mere 1.0% in 1Q27, underscoring tepid demand in core markets and limited volume gains. (Reuters)
The sharp rise in operating income primarily reflected cost reductions and favorable mix rather than meaningful organic sales acceleration, raising questions about sustainability absent stronger revenue momentum. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2026.
MLAB Financial Performance
Revenues and expenses
MLAB Earnings Performance
Company profitability
Upcoming events
No upcoming events
MLAB News
AllArticlesVideos
Funds containing MLAB
AllUSDEURGBP
Fund name | Fund size | $MLAB weighting |
|---|---|---|
iShares Automation & Robotics$RBOT | $5.2B | 0.03% |
iShares Automation & Robotics€2B76 | €4.5B | 0.03% |
iShares Automation & Robotics£RBTX | £3.8B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.